CHARM Therapeutics Receives Investment for Deep Learning-Enabled Drug Discovery Research from NVIDIA
Summary
The investment represents a major milestone for CHARM, enabling the company to further deliver on its research and development activities in the area of novel medicines for oncology.CHARM is at the forefront of deep learning-enabled drug discovery research, utilizing advanced computing and machine learning to develop novel small molecule therapeutics for cancers that have long been considered difficult to drug. "We are thrilled to be collaborating with NVIDIA as they share our vision for the future of drug discovery," said Laksh Aithani, CEO and co-founder of CHARM. "With this investment and continued use of NVIDIAs advanced computing technology, we believe we can accelerate the development of our small molecule therapies, bringing them to patients faster and more efficiently than ever before. Powered by the first high throughput protein-ligand co-folding algorithm and a world-class team of scientists and engineers, CHARM seeks to deliver innovative approaches to create life-changing therapies for patients.London-based CHARM has raised $70 million to date and is building an interdisciplinary and entrepreneurial team, combining leaders from the fields of AI and biotechnology. It is supported by high quality international investors including OrbiMed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA and grep -vc.